AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumour cells to divide without undergoing the normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone.
Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee.
In addition Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing.
"MK-1775 is a strong addition to AstraZeneca's growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response," said Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. "The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need."
"Merck is committed to advancing potentially meaningful therapeutic options promptly for patients with cancer," said Iain D. Dukes, senior vice president and head of licensing and external scientific affairs at Merck. "We are pleased to enter this agreement with AstraZeneca to realise the potential of MK-1775 while we focus on advancing our later stage oncology programs, MK-3475 and vintafolide."
The agreement is contingent on expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvement Act.
About MK-1775
WEE1 is a cell cycle checkpoint protein regulator. Preclinical data indicate that disruption of WEE1 may enhance the cell killing effects of some anticancer agents. MK-1775 is an investigational orally available inhibitor of the cell cycle checkpoint protein WEE1. MK-1775 is being evaluated in Phase IIa clinical trials for the treatment of patients with P53-deficient ovarian cancer.